The Pharma Data

AUGUST 17, 2020

DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

MAY 6, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Pfizer Inc. Food and Drug Administration (FDA) to expand the approval of COMIRNATY® (COVID-19 Vaccine, mRNA) to include individuals ages 12 through 15 years.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

The Pharma Data

JANUARY 24, 2021

JCI Insight 2019. ZUG, Switzerland , Jan. The majority of deaths (around 90%) associated with cancer are due to the metastasis of the original tumor cells to sites distant from the initial or primary tumor 1. Chief Medical Officer of Quercis Pharma. Chairman and Chief Executive Officer Quercis Pharma ilaeber@quercis.com.

Licensing 40

Licensing Licensing Clinical Trials Medical Schools 40

Perficient: Drug Development

AUGUST 2, 2023

SVS is designed to work with a command line in the background and also provides an interactive interface in Visual Studio 2019. SVS requires a license; we can utilize the same license as Sitecore TDS. If you don’t have a license, then you can purchase from the TDS site.

Packaging 52

Packaging Licensing Licensing Trials 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. February 2019.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019. VICTORIA, British Columbia & ROCKVILLE, Md.–(

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

DECEMBER 21, 2020

from the University of New Hampshire in Durham, and colleagues used data from the Current Population Survey (2010 to 2019) to document the rate of nursing and long-term care workers who hold second jobs. percent of licensed practical nurses and registered nurses held second jobs. Baughman, Ph.D.,

Nurses 52

Nurses Licensing Licensing Research 52

The Pharma Data

NOVEMBER 23, 2020

. The Company previously presented its plan of compliance to the NYSE American on December 19, 2019 in response to a notice dated November 25, 2019 that the Company was below compliance with certain NYSE American continued listing standards, as set forth in Section 1003(a)(iii) of the NYSE American Company Guide, since it reported (..)

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

JANUARY 18, 2021

In total, there were 31 mostly virtual expert panel meetings in 2020, but more than a dozen of those did not involve votes on New Drug Applications (NDAs), Biologics License Applications (BLAs) or new indications, but instead focused on devices, tobacco or other topics. 9, 2020 ).

FDA 52

FDA FDA Approval Licensing Licensing 52

New Drug Approvals

SEPTEMBER 29, 2024

gingivalis DNA was detected in postmortem cortices from people with AD and healthy controls, and in CSF of AD patients ( Jan 2019 news on Dominy et al., Findings Two Phase 1 trials of atuzaginstat were completed by June 2019. 2019 Jan;5(1):eaau3333. Epub 2019 Jan 23 PubMed.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

JANUARY 17, 2021

Launched in 2019, the company raised $700 million in June 2020 in its initial financing. Shortly after its 2019 launch, the company licensed technology from Harvard University that could potentially improve the success of cell therapy treatments. Loxo sold to Eli Lilly in 2019 for about $8 billion.

Marketing 52

Marketing Engineering Therapies Disease 52

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

The Pharma Data

NOVEMBER 29, 2020

2019, 62 , 445?447. On October 28, 2019 , Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors. About Ascentage Pharma. Ascentage Pharma (6855.HK)

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

DECEMBER 21, 2020

The FDA granted cilta-cel Breakthrough Therapy and Orphan Drug designations in 2019, and the therapy received a PRIME Priority Medicines designation from the European Commission (EC) that same year and an Orphan Drug designation from the EC in February 2020.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

Perficient: Drug Development

JULY 24, 2023

SDK Visual Studio 2019/2022 Docker for Windows, with Windows Containers enabled Hyper-v After cloning a SitecoreHeadlessStarterKit repository in my local machine, the next step was to spin a Docker instance. Before running the first command, make sure that the Sitecore license is placed in the correct folder on your local machine.

Licensing 52

Licensing Licensing 52

The Pharma Data

JANUARY 14, 2021

Before today’s announcement, physicians wishing to prescribe buprenorphine outside of opioid treatment programs had to take an eight-hour course and often waited 60 to 90 days to receive the waiver once the course is completed and the license application is submitted. Added Dr. Rosenberg, “This is a great day for our patients.

Treatment 52

Treatment Licensing Licensing Hospitals 52

New Drug Approvals

AUGUST 21, 2023

4] [5] History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. 21] Phase III In December 2019, Ipsen issued a partial clinical hold for people under the age of 14, due to reports of early fusion of growth plates. [22] 22] Ipsen acquired Clementia in 2019.

FDA 52

FDA Clinical Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 17, 2021

. “Rolontis,” a treatment for neutropenia that had its technology licensed out to Spectrum Pharmaceuticals, Inc. and “Oraxol,” which was licensed out to Athenex, Inc. Belvarafenib (HM95573, solid tumor) , which was licensed to Genentech, Inc., Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Broad Institute

FEBRUARY 29, 2024

By Leah Eisenstadt February 29, 2024 Credit: Courtesy of (clockwise, from top left) National Park Service; Rainer Zenz, Creative Commons license; Len Charnoff/Flickr, public domain; Riki7, public domain; National Park Service; Rufus46, Creative Commons. million deaths globally.

Hospitals 116

Hospitals Medical Schools International Research 116

The Pharma Data

JANUARY 25, 2021

Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. Velazquez and Jun Zhao-Liu.

Therapies 52

Therapies Disease Licensing Licensing 52

The Pharma Data

NOVEMBER 23, 2020

His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

AUGUST 6, 2020

AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. That has changed. The vaccine was moved into phase 2/3 in May.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

AUGUST 21, 2020

Lilly first licensed Tyvyt from Innovent in 2015. The original deal included rights outside of China, but in 2017, Lilly licensed back those rights while retaining downstream economics, Taylor said. Through a 2019 deal, Innovent also licensed China rights to Lilly’s dual GLP-1 and GCGR agonist OXM3 as a potential diabetes therapy.

Licensing 52

Licensing Licensing FDA Therapies 52

DrugBank

DECEMBER 4, 2024

Still, it also provides flexibilities, such as compulsory licensing and parallel importation, that LMIC can utilize to improve access to medicines. A 2019 WHO report found that in LMIC, out-of-pocket expenditure accounts for over 50% of total health expenditure, compared to less than 20% in HIC. 

Drugs 52

Drugs Licensing Licensing Pharmaceutical Companies 52

The Pharma Data

OCTOBER 22, 2020

The collaboration will make trusted, public health information available under the Creative Commons Attribution-ShareAlike license at a time when countries face continuing resurgences of COVID-19 and social stability increasingly depends on the public’s shared understanding of the facts. . About the World Health Organization.

Licensing 52

Licensing Licensing International Government 52

The Pharma Data

DECEMBER 13, 2020

MacroGenics , based in Rockville, Maryland, has a target action date of December 18 for its Biologics License Application (BLA) for margetuximab in combination with chemotherapy for patients with metastatic HER2+ breast cancer. Read on for this week’s. MacroGenics’ Margetuximab for Metastatic HER2+ Breast Cancer.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Licensing 40

Licensing Licensing Pharmaceutical Companies Engineering 40

The Pharma Data

MARCH 15, 2022

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc.,

Trials 52

Trials FDA Disease Licensing 52

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. Focused on healthcare, deep tech and new digital economy, VVC has been named “ China’s TOP 20 Healthcare VC firms of 2019-2020″ by 36Kr. View original content: [link].

Clinical Trials 40

Clinical Trials Licensing Licensing Drug Development 40

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. million for the quarter ended September 30, 2019 (the “2019 Quarter”) and $33.6 million for the 2019 Quarter and $44.5 million for the 2019 Quarter.

Pharmaceuticals 52

Pharmaceuticals Production Marketing Pharmaceutical Companies 52

PLOS: DNA Science

SEPTEMBER 7, 2023

Now, college tuition includes a fee to license an e-textbook for a limited time. ChatGPT apparently didn’t read my article, Anatomy of an Impossible Burger , which I posted here at DNA Science in May 2019. Tomes were split into shorter versions, like calving icebergs. The first E-books date from the 1990s.

DNA 98

DNA Science Therapies Licensing 98

The Pharma Data

MARCH 16, 2021

In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. AUTHORIZED USE IN THE U.S.:

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

DECEMBER 2, 2020

The Phase IIb induction study in patients with moderate-to-severe UC, enrolled the first patient in August 2019. Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. Horizon Discovery Group – U.K.-based

Licensing 52

Licensing Licensing DNA Vaccine 52